ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.185
-0.02%
US Dollar vs AUD
1.5028
0.40%
Bitcoin
66,158.86
1.41%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) News

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RVNC
DateTimeSourceHeadlineSymbolCompany
10/05/202406:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
10/05/202406:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
10/05/202406:06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
10/05/202406:05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
03/05/202406:05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
12/04/202422:00Business WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
28/03/202407:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
09/03/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
06/03/202409:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
06/03/202409:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
05/03/202409:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202409:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202408:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202408:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202401:25Business WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
04/03/202422:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
04/03/202422:37Business WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
01/03/202408:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
29/02/202408:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
29/02/202408:05Business WireRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
22/02/202400:01Business WireRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024NASDAQ:RVNCRevance Therapeutics Inc
22/02/202400:00Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
15/02/202407:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
14/02/202408:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
14/02/202401:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
07/02/202408:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
03/02/202408:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/02/202408:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/02/202408:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/02/202400:00Business WireRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®NASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Your Recent History

BIT
NRAM
Amundi Index MSCI North ...
COIN
TTCGBP
KUCN
MNWUSDT
Morpheus.Network
AMEX
HIDE
Alpha Architect High Inf...
COIN
KDAGGBP
EU
H849S
H849S
COIN
WNDDUST
WND (WonderHero)
EU
CMSG
CAC Mid and Small Gross ...
AMEX
BWP
LSE
78HQ
Anz Bank 13
EU
ATLA
Fonciere Atland SA 4.95%...
COIN
OHMSETH
LSE
NIOX
Niox
COIN
FLTEUR
LSE
74FT
Abu Dhabi.24 S
GDAX
ENSUSDT
Ethereum Name Service
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved